Probes For Detection Of Animal Nucleotide Sequences Patents (Class 536/24.31)
-
Patent number: 11485966Abstract: The present invention provides a method for improving the loading of nucleic acid on a solid support by contacting the solid support with a poloxamer-containing reagent. The present invention also provides a method for improving the stability of a nucleic acid on a solid support, comprising contacting a nucleic acid molecule with a partially double-strand oligonucleotide before or after loading the nucleic acid molecule on a solid support, so as to cause the nucleic acid molecule to hybridize with the oligonucleotide. The present invention also provides a combined use of the two methods.Type: GrantFiled: October 11, 2017Date of Patent: November 1, 2022Assignees: MGI TECH CO., LTD., COMPLETE GENOMICS, INC.Inventors: Hui Wang, Xun Xu, Jin Yang, Ao Chen, Chongjun Xu, Wenwei Zhang
-
Patent number: 11414666Abstract: The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.Type: GrantFiled: June 23, 2017Date of Patent: August 16, 2022Assignees: UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: François Giuliano, Alberto Epstein, Olivier Le Coz, Alejandro Aranda
-
Patent number: 11406691Abstract: The invention provides an AMH-INH-GNIH tri-expression gene vaccine capable of improving fecundity of animals and a preparation method of engineering strain thereof. The engineering strain was deposited in China Center for Type Culture Collection on Aug. 15, 2018, with deposit No.: CCTCC NO:M 2018544. When the engineering strain is used for direct immunization of animals or immunization of animals after being mixed with DNA vaccine adjuvant, the fecundity of the animals can be effectively improved. The tri-expression gene is a tri-expression non-resistant DNA plasmid of Mullerian duct resisting hormone, inhibin and gonadotropin release restraining hormone, which can be used for direct immunization of the animals through mucosa immunization to generate antibodies in the manner of being sprayed to noses, orally administered, blended into feeds and the like.Type: GrantFiled: September 18, 2020Date of Patent: August 9, 2022Assignee: Huazhong Agricultural UniversityInventors: Liguo Yang, Jiaomei Tang, Qunli Zhou, Aixin Liang, Aizhen Guo
-
Patent number: 10378016Abstract: The invention provides aptamer-gene modulator conjugates, where the aptamer and the gene modulator are linked together. The invention further provides a method for cell-specific delivery of gene modulators to hard to transfect cells such as CD4+ cell.Type: GrantFiled: December 6, 2011Date of Patent: August 13, 2019Assignee: Children's Medical Center CorporationInventors: Judy Lieberman, Lee Adam Wheeler
-
Patent number: 9752187Abstract: The present application describes methods for accurate and cost-effective categorization of DNA samples into different types of in vitro generated DNA or different types of natural DNA such as from different tissues and/or physiological/pathological states. The invention achieves categorization by comparing “signal ratios” that are correlated to ratios of methylation levels at specific genomic loci, but does not rely on calculation of actual methylation levels at any genomic locus. Therefore the disclosed inventive method eliminates the requirement for external DNA species and controls, thereby simplifying and increasing the accuracy of the assay. The described inventive technology also enables performing the categorization of DNA together with DNA profiling in the same reaction, thereby allowing for concomitant categorization and determination of identity of the samples.Type: GrantFiled: June 8, 2012Date of Patent: September 5, 2017Assignee: NucleixInventors: Adam Wasserstrom, Danny Frumkin
-
Patent number: 9730979Abstract: The present invention provides methods for modulating SET activity by contacting SET with a binding agent such as an ApoE peptide derivative. In one embodiment of the invention, a pharmaceutical composition capable of modulating SET activity is administered to a patient for the treatment of an inflammatory or neurological condition. In another embodiment of the invention, compounds efficacious for the treatment of inflammatory and neurological conditions are identified by screening for a binding agent capable of competing with or inhibiting the binding of an ApoE derivative to SET.Type: GrantFiled: December 21, 2007Date of Patent: August 15, 2017Assignee: COGNOSCI, INC.Inventors: Michael P. Vitek, Dale J. Christensen, Jessica Oddo
-
Patent number: 9173943Abstract: The present invention relates to imprinted polymer nanoparticles. In particular, the present invention provides imprinted polymer nanoparticles polymerized in the presence of a target molecule (e.g., peptide), wherein the imprinted polymer nanoparticles comprise vinyl, acryl, and/or methacryl monomers, wherein the monomers have affinity for the target molecule. The present invention also relates to methods of using imprinted polymer nanoparticles in biomacromolecular purification methods (e.g., to purify monoclonal antibodies or hormones), in toxin elimination methods (e.g., hemoperfusion), in diagnostics, in research, as well as in therapeutic methods (e.g., therapeutic methods where antisera or monoclonal antibodies are normally employed).Type: GrantFiled: January 11, 2010Date of Patent: November 3, 2015Assignee: The Regents of the University of CaliforniaInventors: Yu Hoshino, Kenneth J. Shea
-
Patent number: 9145561Abstract: The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the Agaricus bisporus lectin gene. The sequences drive expression preferentially to fruit body tissue. A method for expressing a nucleotide sequence in fungi using the regulatory sequences disclosed herein is provided. The method comprises transforming a fungal cell to comprise a nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed fungus from the transformed cell.Type: GrantFiled: August 30, 2011Date of Patent: September 29, 2015Assignee: Interexon CorporationInventors: Zhixin Shi, Jack Q. Wilkinson, Donald S. Walters, C. Peter Romaine
-
Patent number: 9145449Abstract: The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide. Methods of inhibiting cancer cells growth are also disclosed, comprising administering the isolated polypeptide or the antibody described herein to a subject in need thereof.Type: GrantFiled: February 4, 2014Date of Patent: September 29, 2015Assignee: CHANG GUNG MEMORIAL HOSPITAL, LINKOU BRANCHInventors: Tzu-Hao Wang, Chia-Lung Tsai, Angel Chao
-
Patent number: 9140707Abstract: A method for generating antibodies preferable to either a normal protein and a mutated form of the normal protein, respectively, where a mutation associated with the mutated form includes either a single point mutation or a small number of point mutations where the method includes creating first and second antigenic peptides of a predetermined length corresponding respectively to common regions of the normal target protein and the mutated form, where the common regions are identical to one another except for the point mutation of the mutated form, obtaining first and second antibodies by multiplying the first and second antigenic peptides via hybridoma methods, and identifying the respective affinities of the first and second antibodies for the normal target protein and the mutated form. Also included are methods of using the first and second antibodies to detect and quantify respective amounts of a normal target protein and a mutated form of the target protein.Type: GrantFiled: August 10, 2007Date of Patent: September 22, 2015Assignee: University of Louisville Research Foundation, Inc.Inventors: Kyung Aih Kang, Stephen Peiper
-
Patent number: 9063139Abstract: Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.Type: GrantFiled: August 2, 2011Date of Patent: June 23, 2015Assignees: The Trustees of Columbia University in the City of New York, University of Iowa Research Foundation, The United States of America, As Represented By the Secretary of the Department of Health and Human ServicesInventors: Rando L. Allikmets, Gregory S. Hageman, Michael C. Dean, Albert M. Gold
-
Publication number: 20150141391Abstract: The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.Type: ApplicationFiled: October 14, 2014Publication date: May 21, 2015Inventors: Arul M. Chinnaiyan, Dan Robinson, Yi-Mi Wu
-
Publication number: 20150141277Abstract: A method for the measurement of the amount or difference in the amounts of 2 or more nucleic acid targets in a sample, the method comprising the steps of attaching to nucleic acids present in the sample (1) a tag which allows the nucleic acids to be captured to a solid support; and (2) a labelled probe for a first nucleic acid target present in the sample and a labelled probe for second nucleic acid target present in the sample, and then measuring the amount of each labelled probe or difference in the amount of labelled probes; wherein the probe is not a single labelled nucleotide.Type: ApplicationFiled: May 17, 2013Publication date: May 21, 2015Inventors: Edwin Southern, Dietrich Lueerssen, Oliver Miller, Natalie Milner
-
Publication number: 20150141287Abstract: Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided.Type: ApplicationFiled: January 22, 2015Publication date: May 21, 2015Inventor: John B. Vincent
-
Patent number: 9034837Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.Type: GrantFiled: April 26, 2010Date of Patent: May 19, 2015Assignee: Roche Innovation Center Copenhagen A/SInventors: Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford
-
Patent number: 9035036Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.Type: GrantFiled: May 17, 2013Date of Patent: May 19, 2015Assignees: The General Hospital, Dana-Farber Cancer Institute, Inc.Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
-
Publication number: 20150133333Abstract: Disclosed are kits and methods for diagnosing a person with, or assessing a person's risk for developing, sarcoidosis and/or complicated sarcoidosis.Type: ApplicationFiled: September 11, 2014Publication date: May 14, 2015Inventors: Joe G.N. Garcia, Tong Zhou, Wei Zhang, Roberto Machado
-
Patent number: 9029084Abstract: A polynucleotide primer comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 1 to 18, 21 to 45 or 74 to 77.Type: GrantFiled: April 4, 2006Date of Patent: May 12, 2015Assignee: Qiagen Manchester LimitedInventors: David Mark Whitcombe, Nicola Jo Thelwell, Paul Francis Ravetto
-
Publication number: 20150125868Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.Type: ApplicationFiled: October 10, 2014Publication date: May 7, 2015Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: VÉRONIQUE GELSI-BOYER, DANIEL BIRNBAUM
-
Publication number: 20150126399Abstract: The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample.Type: ApplicationFiled: January 8, 2015Publication date: May 7, 2015Inventors: Ranit Aharonov, Nitzan Rosenfeld, Hila Benjamin
-
Publication number: 20150118155Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.Type: ApplicationFiled: June 14, 2012Publication date: April 30, 2015Applicant: Hill's Pet Nutrition, Inc.Inventors: Samer Al-Murrani, Xiangming Gao
-
Publication number: 20150110733Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identifType: ApplicationFiled: October 21, 2014Publication date: April 23, 2015Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Amir TCHELET, Michael HAYDEN, Liat HAYARDENY, Colin James Douglas ROSS, Iris GROSSMAN, David LADKANI
-
Patent number: 9012619Abstract: Detection probes are provided that are capable of detecting a sequence to be detected containing a mutation even when a sequence not to be detected containing no mutation coexists with the sequence to be detected containing a mutation, which are different only in a single base from each other. At least one oligonucleotide selected from the group consisting of SEQ ID NOs: 2˜16 is used as a probe. Even in a sample containing an abl gene in which a mutation has occurred and an abl gene in which no mutation has occurred, the use of such probes in, for example, Tm analysis allows the mutation to be detected.Type: GrantFiled: February 19, 2008Date of Patent: April 21, 2015Assignee: Arkray, Inc.Inventors: Mitsuharu Hirai, Satoshi Majima, Taira Maekawa, Shinya Kimura
-
Patent number: 9006199Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.Type: GrantFiled: November 14, 2012Date of Patent: April 14, 2015Assignee: Silenseed Ltd.Inventors: Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai
-
Publication number: 20150099747Abstract: The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.Type: ApplicationFiled: October 7, 2014Publication date: April 9, 2015Inventors: Xiaoju Max Ma, Chitra Manohar, Alison Tsan
-
Patent number: 9000144Abstract: In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, (miRNAs), exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.Type: GrantFiled: May 16, 2012Date of Patent: April 7, 2015Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Thomas Tuschl, Mariana Lagos-Quintana, Winfried Lendeckel, Jutta Dammann, Reinhard Rauhut
-
Patent number: 9000142Abstract: There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently bound to the antisense nucleobase polymer, wherein the photocleavable sense nucleobase polymer comprises a plurality of nucleobase polymers connected by a photocleavable linkage. There is also disclosed a method for controlling the time and spatial position of gene expression comprising selecting a target mRNA, introducing the photocleavable sense-antisense nucleobase polymer complex into a cell, and selectively irradiating the cell with light.Type: GrantFiled: June 23, 2009Date of Patent: April 7, 2015Assignee: Syntrix Biosystems, Inc.Inventor: John A. Zebala
-
Patent number: 8999648Abstract: A system (100) for classifying a biological test sample, including a database (112) populated with reference expression data. The reference expression data includes expression levels of a plurality of molecules (polynucleotides or polypeptides), including a set of marker molecules, in a plurality of reference samples. Each reference sample has a pre-assigned value for each of one or more clinically significant variables. The system includes at least one processor (110) and at least one storage medium containing program instructions for execution by said processor (110). The program instructions cause the processor to accept (122) input expression data including a test vector of expression levels of the marker molecules in the biological test sample; and pass the input expression data to one or more analysis programs (130a, 130b, 35).Type: GrantFiled: September 30, 2010Date of Patent: April 7, 2015Assignee: Signal Genetics, Inc.Inventor: Ryan Van Laar
-
Publication number: 20150094231Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: ApplicationFiled: December 12, 2014Publication date: April 2, 2015Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
-
Publication number: 20150088430Abstract: The invention in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention.Type: ApplicationFiled: April 26, 2013Publication date: March 26, 2015Inventor: Duncan H. Whitney
-
Patent number: 8987435Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.Type: GrantFiled: October 23, 2009Date of Patent: March 24, 2015Assignee: Isis Pharmaceuticals, Inc.Inventors: Eric E. Swayze, Balkrishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
-
Patent number: 8987222Abstract: The present invention relates to the discovery of (SNPs) significantly associated with Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against such SNPs optimally combined with select additional SNP targeting silencing agents, thereby resulting in an effective treatment of significantly-sized patient populations. Silencing agents having enhanced discriminatory properties are also featured.Type: GrantFiled: April 8, 2010Date of Patent: March 24, 2015Assignee: University of MassachusettsInventors: Neil Aronin, Edith Pfister, Phillip D. Zamore
-
Publication number: 20150080235Abstract: Described herein are compositions and methods for diagnosing or monitoring type 1 diabetes.Type: ApplicationFiled: September 18, 2014Publication date: March 19, 2015Inventor: Sahar Usmani-Brown
-
Publication number: 20150072345Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.Type: ApplicationFiled: September 11, 2014Publication date: March 12, 2015Inventors: Sergei M. Gryaznov, Ronald G. Schultz
-
Publication number: 20150074836Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.Type: ApplicationFiled: August 7, 2014Publication date: March 12, 2015Applicants: Aventis Pharma S.A., Institut National de la Santé et de la Recherche MédicaleInventors: Alexis Brice, Christophe Lucking, Patrice Denefle
-
Patent number: 8975237Abstract: Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.Type: GrantFiled: December 22, 2008Date of Patent: March 10, 2015Assignee: CoDa Therapeutics, Inc.Inventors: David L. Becker, Colin R. Green, Bradford James Duft
-
Publication number: 20150065380Abstract: The present invention relates to epilepsy-inducing brain somatic mutations which are associated with intractable epilepsy caused by malformations of cortical development, and uses thereof. More particularly, the present invention relates to an mTOR (Mammalian target of rapamycin) gene having mutations in a nucleotide sequence or an mTOR protein having mutations in an amino acid sequence resulting from the mutations in the nucleotide sequence. Further, the present invention relates to a technique for diagnosing intractable epilepsy caused by malformations of cortical development using the gene or the protein.Type: ApplicationFiled: September 2, 2014Publication date: March 5, 2015Inventors: Jeong Ho LEE, Dong Seok Kim, Hoon Chul Kang, Jae Seok Lim, Woo-II Kim
-
Publication number: 20150065378Abstract: Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, PCR primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides.Type: ApplicationFiled: August 28, 2014Publication date: March 5, 2015Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: William Mathers, Zheng Ye
-
Patent number: 8962582Abstract: The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease or disorder. The RNA polymers are preferably able to activate the RNA-dependent kinase PKR. Activation of PKR via RNA-HCR can be used to treat a wide variety of diseases and disorders by specifically targeting diseased cells.Type: GrantFiled: June 7, 2011Date of Patent: February 24, 2015Assignee: California Institute of TechnologyInventors: Robert Dirks, Niles A. Pierce
-
Publication number: 20150051084Abstract: A method for determining the prognosis of prostate cancer in a subject is provided which comprises the assessment of the methylation status of the HSPB1 gene in a prostate cancer sample.Type: ApplicationFiled: March 19, 2013Publication date: February 19, 2015Inventors: Attila Lorincz, Natasa Vasiljevic, Amar Ahmad
-
Publication number: 20150051103Abstract: Methods of detecting cervical dysplasia, such as cervical dysplasia likely to progress to carcinoma in a sample of human cervical cells, are provided. Methods of detecting changes in expression of one or more microRNAs or mRNAs associated with cervical dysplasia or cervical cancer are also provided. Compositions and kits are also provided.Type: ApplicationFiled: July 29, 2014Publication date: February 19, 2015Inventors: Cecilia Svanholm Barrie, Olivier Delfour, David H. Persing
-
Publication number: 20150044205Abstract: The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.Type: ApplicationFiled: August 11, 2014Publication date: February 12, 2015Applicant: GENENTECH, INC.Inventors: Brian Yaspan, Robert Royal Graham, Amy Dressen, Zhengrong Li, Erich Strauss, Teodorica Bugawan
-
Publication number: 20150045243Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of a disease in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of a disease in a body fluid sample from a subject.Type: ApplicationFiled: October 5, 2012Publication date: February 12, 2015Inventors: Andreas Keller, Christina Backes, Markus Beier
-
Publication number: 20150045306Abstract: This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.Type: ApplicationFiled: August 25, 2014Publication date: February 12, 2015Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Amir Tchelet, Fabio Macciardi, Joseph Levy
-
Patent number: 8952145Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: GrantFiled: March 7, 2013Date of Patent: February 10, 2015Assignee: Isis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Publication number: 20150037251Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.Type: ApplicationFiled: February 18, 2013Publication date: February 5, 2015Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICASInventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
-
Patent number: 8945846Abstract: Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.Type: GrantFiled: January 12, 2011Date of Patent: February 3, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jason Robert Gotlib, Garry P. Nolan, James L. Zehnder, Stephen Tracy Oh
-
Publication number: 20150031749Abstract: A method of determining the Crohn's disease status of a subject comprising the steps of determining the level of miR-29 in a sample from said subject; and comparing the level of miR-29 determined in step (a) with one or more reference values.Type: ApplicationFiled: March 12, 2013Publication date: January 29, 2015Applicant: Isis Innovation LimitedInventor: Alison Simmons
-
Patent number: 8940504Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: GrantFiled: March 13, 2012Date of Patent: January 27, 2015Assignee: Novo Nordisk Healthcare AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Patent number: 8940479Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.Type: GrantFiled: January 14, 2009Date of Patent: January 27, 2015Assignee: Cornell UniversityInventors: Ann-Hwee Lee, Laurie H. Glimcher